PTC Therapeutics Company Profile (NASDAQ:PTCT)

About PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics logoPTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTCT
  • CUSIP: N/A
  • Web:
  • Market Cap: $728.78 million
  • Outstanding Shares: 41,304,000
Average Prices:
  • 50 Day Moving Avg: $19.24
  • 200 Day Moving Avg: $16.77
  • 52 Week Range: $4.03 - $22.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.03
  • P/E Growth: 0.79
Sales & Book Value:
  • Annual Revenue: $122.69 million
  • Price / Sales: 5.99
  • Book Value: $4.11 per share
  • Price / Book: 4.33
  • EBITDA: ($90,430,000.00)
  • Net Margins: -88.43%
  • Return on Equity: -81.84%
  • Return on Assets: -36.49%
  • Debt-to-Equity Ratio: 0.83%
  • Current Ratio: 3.34%
  • Quick Ratio: 3.24%
  • Average Volume: 1.00 million shs.
  • Beta: 1.37
  • Short Ratio: 12

Frequently Asked Questions for PTC Therapeutics (NASDAQ:PTCT)

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.45. The business had revenue of $47.96 million for the quarter, compared to analyst estimates of $28.78 million. PTC Therapeutics had a negative return on equity of 81.84% and a negative net margin of 88.43%. The firm's revenue for the quarter was up 206.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.14) earnings per share. View PTC Therapeutics' Earnings History.

When will PTC Therapeutics make its next earnings announcement?

PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for PTC Therapeutics.

Where is PTC Therapeutics' stock going? Where will PTC Therapeutics' stock price be in 2017?

9 brokers have issued 1-year price targets for PTC Therapeutics' stock. Their predictions range from $7.00 to $28.00. On average, they expect PTC Therapeutics' share price to reach $16.38 in the next year. View Analyst Ratings for PTC Therapeutics.

What are analysts saying about PTC Therapeutics stock?

Here are some recent quotes from research analysts about PTC Therapeutics stock:

  • 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (10/11/2017)
  • 2. Cowen and Company analysts commented, "PTCT announced 4Q16 results today: Translarna EU sales continue to grow." (3/16/2017)
  • 3. Royal Bank Of Canada analysts commented, "PTCT has announced it has filed its NDA for ataluren with FDA under protest and that the filing has been acknowledged: Recall that the FDA issued a Refuse-to-File letter on 2/23/16. The NDA was initially filed on 1/8/16 and was based on the results of the confirmatory Phase III ACTDMD trial, released 10/15/15, which failed to meet its primary endpoint. We continue to see very little chance that ataluren gets approved in the US, given compelling evidence from multiple randomized clinical trials where this compound failed to meet its primary endpoint. We believe that despite what looks like an improving/lower-threshold FDA environment, the only way this compound can get approval is if it succeeds in a new Phase III trial. Absent that, we believe that the key opportunity to evaluate in PTCT shares are Translarna ex-US sales, which we view as fully valued at current levels. We reiterate our Sector Perform rating on PTCT." (3/6/2017)
  • 4. Jefferies Group LLC analysts commented, "PTCT reported ~$81M Translarna net sales in 2016 (higher vs. our est of $75M) and guided $105-125M for 2017 sales. The topline data for Translarna Ph3 study in CF continues to be expected in late-1Q17 and the company plans to file NDA in DMD over protest in the US. Additional pipeline in SMA and cancer are progressing on-track." (1/10/2017)

Who are some of PTC Therapeutics' key competitors?

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the folowing people:

  • Michael Schmertzler, Independent Chairman of the Board
  • Stuart W. Peltz Ph.D., Chief Executive Officer, Director
  • Christine Marie Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer
  • Marcio Souza, Chief Operating Officer
  • Mark E. Boulding, Executive Vice President, Chief Legal Officer and Corporate Secretary
  • Neil Almstead Ph.D., Executive Vice President, Research, Pharmaceutical Operations & Technology
  • Tuyen Ong, Chief Medical Officer
  • Allan S. Jacobson Ph.D., Independent Director
  • David P. Southwell, Independent Director
  • Glenn D. Steele Jr., M.D., Ph.D., Independent Director

Who owns PTC Therapeutics stock?

PTC Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.42%). Company insiders that own PTC Therapeutics stock include Dawn Svoronos, Mark Rothera and Neil Gregory Almstead. View Institutional Ownership Trends for PTC Therapeutics.

Who bought PTC Therapeutics stock? Who is buying PTC Therapeutics stock?

PTC Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have bought PTC Therapeutics stock in the last two years include Dawn Svoronos and Mark Rothera. View Insider Buying and Selling for PTC Therapeutics.

How do I buy PTC Therapeutics stock?

Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTC Therapeutics stock can currently be purchased for approximately $17.79.

MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  286 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $16.38 (7.95% downside)
Consensus Price Target History for PTC Therapeutics (NASDAQ:PTCT)
Price Target History for PTC Therapeutics (NASDAQ:PTCT)
Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017J P Morgan Chase & CoDowngradeNeutral -> Underweight$23.00 -> $15.00N/AView Rating Details
9/29/2017Royal Bank Of CanadaReiterated RatingSector Perform -> Sector PerformHighView Rating Details
9/29/2017Barclays PLCLower Price TargetEqual Weight -> Equal Weight$22.00 -> $15.00HighView Rating Details
9/27/2017Citigroup Inc.Reiterated RatingBuy$28.00LowView Rating Details
9/26/2017Credit Suisse GroupReiterated RatingOutperform$25.00HighView Rating Details
8/23/2017William BlairInitiated CoverageMkt Perform -> Market Perform$17.00LowView Rating Details
3/16/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
1/10/2017Jefferies Group LLCReiterated RatingHold$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$12.00 -> $7.00N/AView Rating Details
10/3/2016Bank of America CorporationReiterated RatingHold$15.00N/AView Rating Details
4/17/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$39.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for PTC Therapeutics (NASDAQ:PTCT)
Earnings by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Earnings History by Quarter for PTC Therapeutics (NASDAQ PTCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.48)N/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.44)$28.78 million$47.96 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.88)($0.85)$27.93 million$26.50 millionViewListenView Earnings Details
3/16/201712/31/2016($1.07)($0.78)$24.69 million$25.20 millionViewN/AView Earnings Details
11/2/2016Q316($1.22)($1.03)$19.76 million$23.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.27)($1.14)$15.24 million$15.40 millionViewN/AView Earnings Details
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details
5/6/2014($0.46)($0.58)$10.93 million$9.22 millionViewN/AView Earnings Details
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)
2017 EPS Consensus Estimate: ($2.87)
2018 EPS Consensus Estimate: ($2.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.96)($0.70)($0.83)
Q2 20172($0.93)($0.38)($0.66)
Q3 20173($0.89)($0.32)($0.68)
Q4 20173($0.88)($0.43)($0.70)
Q1 20181($0.81)($0.81)($0.81)
Q2 20181($0.65)($0.65)($0.65)
Q3 20181($0.51)($0.51)($0.51)
Q4 20181($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)


Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for PTC Therapeutics (NASDAQ:PTCT)
Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 81.30%
Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Dawn SvoronosDirectorBuy25,000$13.49$337,250.00View SEC Filing  
1/5/2017Neil Gregory AlmsteadEVPSell78$11.82$921.96View SEC Filing  
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.00View SEC Filing  
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.00View SEC Filing  
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82View SEC Filing  
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.20View SEC Filing  
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.81View SEC Filing  
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.04View SEC Filing  
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.69View SEC Filing  
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.88View SEC Filing  
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.72View SEC Filing  
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.50View SEC Filing  
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74View SEC Filing  
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.36View SEC Filing  
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for PTC Therapeutics (NASDAQ:PTCT)
Latest Headlines for PTC Therapeutics (NASDAQ:PTCT)
Loading headlines, please wait.



PTC Therapeutics (PTCT) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.